Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;37(12):2365-2373.
doi: 10.1038/s41433-023-02433-y. Epub 2023 Feb 14.

Giant cell arteritis: reviewing the advancing diagnostics and management

Edward J Bilton  1   2 , Susan P Mollan  3   4   5
Affiliations
Review

Giant cell arteritis: reviewing the advancing diagnostics and management

Edward J Bilton et al. Eye (Lond). 2023 Aug.

Abstract
in English, Chinese

Giant Cell Arteritis (GCA) is well known to be a critical ischaemic disease that requires immediate medical recognition to initiate treatment and where one in five people still suffer visual loss. The immunopathophysiology has continued to be characterised, and the influencing of ageing in the development of GCA is beginning to be understood. Recent national and international guidelines have supported the directed use of cranial ultrasound to reduce diagnostic delay and improve clinical outcomes. Immediate high dose glucocorticoids remain the standard emergency treatment for GCA, with a number of targeted agents that have been shown in clinical trials to have superior clinical efficacy and steroid sparing effects. The aim of this review was to present the latest advances in GCA that have the potential to influence routine clinical practice.

摘要: 众所周知, 巨细胞动脉炎 (GCA) 是一种严重的缺血性疾病, 需要进行迅速的诊断后才能治疗, 但五分之一的患者仍会导致视力损伤。其免疫病理生理学特征正不断地被描述出来, 人们也逐渐意识到衰老对GCA进展的影响。新近的国家与国际指南中都支持直接使用颅脑超声来减少诊断过程中的延误并改善临床结局。快速使用大量糖皮质激素仍然是GCA的标准急救方法, 尽管一些靶向药物在临床实践中已经证实具有更好的临床疗效且具有类固醇的效果。本综述旨在介绍GCA的最新进展, 这可能会对日常的临床实践产生影响。.

PubMed Disclaimer

Conflict of interest statement

Dr EJB has no competing interests to declare. Professor SPM reports consultancy fees (Invex Therapeutics); advisory board fees (Invex therapeutics; Gensight) and speaker fees (Heidelberg engineering; Chugai-Roche Ltd; Allergan; Santen; Chiesi; and Santhera).

Figures

Fig. 1
Fig. 1. Schematic highlighting the clinical presentation features of GCA.
These can be cateogorised into vascular symptoms, visual signs, rheumatology and constitutional symptoms.
Fig. 2
Fig. 2
Risk factors for GCA.
See this image and copyright information in PMC

References

    1. Li KJ, Semenov D, Turk M, Pope J. A meta-analysis of the epidemiology of giant cell arteritis across time and space. Arthritis Res Ther. 2021;23:82. doi: 10.1186/s13075-021-02450-w. - DOI - PMC - PubMed
    1. Mollan SP, Begaj I, Mackie S, O’Sullivan EP, Denniston AK. Increase in admissions related to giant cell arteritis and polymyalgia rheumatica in the UK, 2002-13, without a decrease in associated sight loss: potential implications for service provision. Rheumatol (Oxf) 2015;54:375–7. doi: 10.1093/rheumatology/keu433. - DOI - PubMed
    1. De Smit E, Palmer AJ, Hewitt AW. Projected Worldwide Disease Burden from Giant Cell Arteritis by 2050. J Rheumatol. 2015;42:119–25. doi: 10.3899/jrheum.140318. - DOI - PubMed
    1. Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19–30. doi: 10.1136/annrheumdis-2019-215672. - DOI - PubMed
    1. Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology. 2020;59:e1–e23. doi: 10.1093/rheumatology/kez672. - DOI - PubMed

Substances